BioWorld Asia

April 4, 2007

Gene Therapy Gains Boost With $690M Collaboration

LONDON - Big pharma has publicly embraced gene therapy for the first time, with the signing of a $690 million deal between Sanofi-Aventis SA and Oxford BioMedica plc for TroVax. (BioWorld International) Read More

CardioVascular Seeks AIM Status To Negate Naked Short Selling

New Enzyme Technology Could Solve Blood Supply Problems

Evotec Acquires Neuro3d Cash, Assets For $29.4M In Stock

EU Creating Registry To Boost Coordination Of Stem Cell Work

Advanced Therapies Rule Hits New EU Problems

MilleGen and LFB Partner On New Generation of MAbs

Pfizer Initiates Development Of NicOx Glaucoma Drug Candidate

Other News To Note

Nitec Pharma Gets $26M For Lodotra Development

Affibody Issues $28.5M In Shares To Boost New Diagnostic Tool

Today's news in brief

BioWorld

BioWorld briefs for Dec. 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery

BioWorld Science

Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...

Illustration of tau accumulating in a neuron cell.

ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

BioWorld

ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...